Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasm Metastasis 3Melanoma 3Breast Neoplasms 3Waldenstrom Macroglobulinemia 2Virus Diseases 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Recurrence 1Pancreatic Neoplasms 1Pain 1Neuroectodermal Tumors 1Neuroblastoma 1Nervous System Diseases 1Neoplasms, Neuroepithelial 1Neoplasms, Nerve Tissue 1Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Lung Neoplasms 1Liver Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Insulin-Like Growth Factor I, Resistance To 1Humoral Hypercalcemia Of Malignancy 1Gliosarcoma 1Glioma 1Glioblastoma 1Epstein-Barr Virus Infections 1Disease 1

Interventions

Cyclophosphamide 85Rituximab 80Peripheral Blood Stem Cell Transplantation 60fludarabine phosphate 58Filgrastim 40Mycophenolic Acid 37Whole-Body Irradiation 35Cyclosporine 35Radiotherapy 33Etoposide 33Busulfan 33Tacrolimus 31Antilymphocyte Serum 28Melphalan 26Methotrexate 22Prednisone 19Bortezomib 19Methylprednisolone 16Cytarabine 16Vincristine 15Lenalidomide 15Flow Cytometry 14Cord Blood Stem Cell Transplantation 13sargramostim 12Doxorubicin 12Bendamustine Hydrochloride 12fludarabine 11Dexamethasone 11Carmustine 11Carboplatin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma, B-Cell, Marginal Zone × Antibodies, Monoclonal × Clear all
NCT00989586 2017-02-06

Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1/2 Completed
35 enrolled 11 charts
Lymphoid

Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡